VOR NASDAQ
Credit Risk of going bust: lower than 52% of companies Debt: 0.3% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.01 (down 99.9%), Vor Biopharma Inc. would be worth roughly what it owes.
Total debt $2.9M against a stock market value of $993.2M.
Distance to default 5.32 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $1.4M (short-term plus half of long-term), stock volatility 112.1%; Altman Z'' 5.08. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Boston, MA 02116
US
Vor Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to developing innovative engineered hematopoietic stem cell (eHSC) therapies for individuals battling cancer. Its lead product candidate, VOR33, is an eHSC therapy currently undergoing Phase 1/2 clinical trials. VOR33 is designed to target acute myeloid leukemia (AML) and various other hematological malignancies. A key feature of VOR33's eHSCs is their engineered absence of the CD33 protein, which is commonly found on AML blood cancer cells. The company's eHSC platform is intended to enable a range of targeted blood cancer treatments, including CAR-T cell therapies, bispecific antibodies, and antibody-drug conjugates. Vor Biopharma has established a partnership with Akron BioProducts for the development and manufacturing of cGMP nucleases. Established in 2015, the company's headquarters are located in Cambridge, Massachusetts.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| RA CAPITAL MANAGEMEN | M-Exempt | 500 | $12.80 | 2026-10-02 |
| RA CAPITAL MANAGEMEN | M-Exempt | 500 | $12.80 | 2026-10-02 |
| RA CAPITAL MANAGEMEN | S-Sale | 213 | $19.75 | 2026-07-16 |
| ZACCARDELLI DAVID | 0 | — | 2026-07-07 | |
| ZACCARDELLI DAVID | A-Award | 42,658 | $20.10 | 2026-07-07 |